Cosmos Health (NASDAQ:COSM) CEO Purchases $143,756.84 in Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas acquired 388,532 shares of the business’s stock in a transaction on Thursday, February 12th. The stock was acquired at an average cost of $0.37 per share, with a total value of $143,756.84. Following the acquisition, the chief executive officer directly owned 8,861,914 shares in the company, valued at approximately $3,278,908.18. This trade represents a 4.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Grigorios Siokas also recently made the following trade(s):

• On Wednesday, February 11th, Grigorios Siokas purchased 291,262 shares of Cosmos Health stock. The stock was acquired at an average price of $0.41 per share, with a total value of $119,417.42.
• On Friday, January 23rd, Grigorios Siokas purchased 90,325 shares of Cosmos Health stock. The stock was bought at an average price of $0.50 per share, with a total value of $45,162.50.
• On Tuesday, January 20th, Grigorios Siokas purchased 353,321 shares of Cosmos Health stock. The shares were bought at an average cost of $0.50 per share, for a total transaction of $176,660.50.
• On Wednesday, January 14th, Grigorios Siokas acquired 493,495 shares of Cosmos Health stock. The shares were bought at an average price of $0.45 per share, for a total transaction of $222,072.75.
• On Monday, January 12th, Grigorios Siokas acquired 113,185 shares of Cosmos Health stock. The stock was bought at an average cost of $0.50 per share, with a total value of $56,592.50.
• On Thursday, January 8th, Grigorios Siokas bought 156,190 shares of Cosmos Health stock. The shares were bought at an average price of $0.52 per share, with a total value of $81,218.80.
• On Wednesday, January 7th, Grigorios Siokas bought 124,880 shares of Cosmos Health stock. The shares were bought at an average cost of $0.52 per share, for a total transaction of $64,937.60.
• On Tuesday, January 6th, Grigorios Siokas purchased 133,953 shares of Cosmos Health stock. The stock was bought at an average price of $0.54 per share, for a total transaction of $72,334.62.
• On Friday, December 19th, Grigorios Siokas purchased 88,314 shares of Cosmos Health stock. The stock was bought at an average cost of $0.49 per share, with a total value of $43,273.86.
• On Monday, December 15th, Grigorios Siokas acquired 168,472 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.42 per share, with a total value of $70,758.24.

Cosmos Health Trading Up 2.7%

COSM opened at $0.38 on Monday. The stock has a market capitalization of $14.35 million, a price-to-earnings ratio of -0.51 and a beta of 5.36. The company has a quick ratio of 0.84, a current ratio of 0.99 and a debt-to-equity ratio of 0.25. Cosmos Health Inc. has a twelve month low of $0.28 and a twelve month high of $1.32. The company has a 50-day simple moving average of $0.48 and a 200 day simple moving average of $0.72.

Cosmos Health (NASDAQ:COSM) last issued its earnings results on Friday, November 14th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.16). Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. The firm had revenue of $17.11 million during the quarter, compared to analyst estimates of $16.40 million. Analysts predict that Cosmos Health Inc. will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cosmos Health stock. Renaissance Technologies LLC increased its position in shares of Cosmos Health Inc. (NASDAQ:COSM) by 260.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 334,575 shares of the company’s stock after acquiring an additional 241,775 shares during the period. Renaissance Technologies LLC owned about 0.89% of Cosmos Health worth $167,000 at the end of the most recent reporting period. 12.61% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cosmos Health in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.